ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

<p class="MsoNormal">Featuring an interview with Prof Patrick Neven, including the following topics:</p> <ul> <li>Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)</li> <li>Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)</li> <li>Emerging data with novel oral SERD combinations (6:31)</li> <li>Challenges for a general medical oncologist in breast cancer (8:41)</li> <li>Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16)</li> <li>Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16)</li> </ul> <p><a href= "http://m.researchtopractice.com/OncologyToday25/OralSERDsERPosmBC/Video"> CME information and select publications</a></p>